Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a new sedative protect newborn brains during cooling?

NCT ID NCT04772222

First seen Mar 20, 2026 · Last updated Jun 21, 2026 · Updated 13 times

Summary

This study tested a drug called dexmedetomidine in 50 newborns with brain injury who were undergoing cooling therapy. The goal was to see if it could provide sedation and pain relief as well as morphine, but with fewer risks. Researchers measured safety and drug levels in the blood to prepare for a larger future trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOXIC-ISCHEMIC ENCEPHALOPATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Intermountain Medical Center

    Murray, Utah, 84107, United States

  • McKay-Dee Hospital

    Ogden, Utah, 84403, United States

  • Primary Children's Hospital

    Salt Lake City, Utah, 84113, United States

  • University of Utah Health

    Salt Lake City, Utah, 84132, United States

  • Utah Valley Hospital

    Provo, Utah, 84604, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Dexmedetomidine (a sedative and pain reliever that does not slow breathing)

What this could lead to

If it works, this could point toward a safer way to sedate newborns with brain injury during cooling therapy, reducing reliance on opioids.

What could go wrong

This is a small, early-phase trial with only 50 infants, so results may not apply broadly. The drug's safety and effectiveness in this specific group are still unproven.

Conditions

The condition(s) this trial relates to.

brain hypoxia - ischemia Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.